|
1
|
Baniak N, Senger JL, Ahmed S, Kanthan SC
and Kanthan R: Gastric biomarkers: A global review. World J Surg
Oncol. 14:2122016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim HS, Lee H, Jeung HC, Noh SH, Chung HC,
Roh JK, Nam CM and Rha SY: Advanced detection of recent changing
trends in gastric cancer survival: Up-to-date comparison by period
analysis. Jpn J Clin Oncol. 41:1344–1350. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ohtsu A: Chemotherapy for metastatic
gastric cancer: Past, present, and future. J Gastroenterol.
43:256–264. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nagini S: Carcinoma of the stomach: A
review of epidemiology, pathogenesis, molecular genetics and
chemoprevention. World J Gastrointest Oncol. 4:156–169. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang L, Zhou R, Zhao Y, Dong S, Zhang J,
Luo Y, Huang N, Shi M, Bin J, Liao Y and Liao W: MACC-1 promotes
endothelium-dependent angiogenesis in gastric cancer by activating
TWIST1/VEGF-A signal pathway. PLoS One. 11:e01571372016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Katoh M: FGFR inhibitors: Effects on
cancer cells, tumor microenvironment and whole-body homeostasis
(Review). Int J Mol Med. 38:3–15. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kerbel RS: Tumor angiogenesis. N Engl J
Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liang X, Xu F, Li X, Ma C, Zhang Y and Xu
W: VEGF signal system: The application of antiangiogenesis. Curr
Med Chem. 21:894–910. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li T, Liu X, Shen Q, Yang W, Huo Z, Liu Q,
Jiao H and Chen J: Salinomycin exerts anti-angiogenic and
anti-tumorigenic activities by inhibiting vascular endothelial
growth factor receptor 2-mediated angiogenesis. Oncotarget.
7:26580–26592. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma H, Gao L, Li S, Qin J, Chen L, Liu X,
Xu P, Wang F, Xiao H and Zhou S: CCR7 enhances TGF-β1-induced
epithelial-mesenchymal transition and is associated with lymph node
metastasis and poor overall survival in gastric cancer. Oncotarget.
6:24348–24360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kanazawa S, Yamaguchi K, Kinoshita Y,
Komiyama Y, Muramatsu M and Nomura S: Elevation of soluble
interleukin-2 receptor in patients with non-small cell lung cancer
treated with gefitinib. J Cancer Res Clin Oncol. 132:719–725. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Iwamuro M, Shinagawa K, Okada H, Takata K,
Yoshino T and Yamamoto K: Elevated soluble IL-2 receptor levels
correlate with tumor bulk of follicular lymphomas with intestinal
involvement. Clin Biochem. 47:191–195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eller T, Aluoja A, Maron E and Vasar V:
Soluble interleukin-2 receptor and tumor necrosis factor levels in
depressed patients in Estonia. Medicina (Kaunas). 45:971–977.
2009.PubMed/NCBI
|
|
15
|
Ni M, Yang ZW, Li DJ, Li Q, Zhang SH, Su
DF, Xie HH and Shen FM: A potential role of alpha-7 nicotinic
acetylcholine receptor in cardiac angiogenesis in a
pressure-overload rat model. J Pharmacol Sci. 114:311–319. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu N, Zhou N, Chai N, Liu X, Jiang H, Wu
Q and Li Q: Helicobacter pylori promotes angiogenesis depending on
Wnt/beta-catenin-mediated vascular endothelial growth factor via
the cyclooxygenase-2 pathway in gastric cancer. BMC Cancer.
16:3212016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang W, Wang H, Ni Y, Yao Z, Ye L and Tian
J: DCT015, a new sorafenib derivate, inhibits tumor growth and
angiogenesis in gastric cancer models. Tumour Biol. 37:9221–9232.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rubin LA, Galli F, Greene WC, Nelson DL
and Jay G: The molecular basis for the generation of the human
soluble interleukin 2 receptor. Cytokine. 2:330–336. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vuoristo MS, Laine S, Huhtala H, Parvinen
LM, Hahka-Kemppinen M, Korpela M, Kumpulainen E and
Kellokumpu-Lehtinen P: Serum adhesion molecules and interleukin-2
receptor as markers of tumour load and prognosis in advanced
cutaneous melanoma. Eur J Cancer. 37:1629–1634. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
An X, Li M, Li N, Liu B, Zhang H and Wang
J: Effect of heavy-ion beam irradiation on the level of serum
soluble interleukin-2 receptors in hamster cheek pouch carcinoma
model. Biomed Rep. 2:408–411. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim KS, Park JM, Kong T, Kim C, Bae SH,
Kim HW and Moon J: Retinal angiogenesis effects of TGF-β1 and
paracrine factors secreted from human placental stem cells in
response to a pathological environment. Cell Transplant.
25:1145–1157. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Muller-Pillasch F, Menke A, Yamaguchi H,
Elsasser HP, Bachem M, Adler G and Gress TM: TGFbeta and the
extracellular matrix in pancreatitis. Hepatogastroenterology.
46:2751–2756. 1999.PubMed/NCBI
|
|
23
|
Yang XJ, Chen GL, Yu SC, Xu C, Xin YH, Li
TT, Shi Y, Gu A, Duan JJ, Qian C, et al: TGF-β1 enhances
tumor-induced angiogenesis via JNK pathway and macrophage
infiltration in an improved zebrafish embryo/xenograft glioma
model. Int Immunopharmacol. 15:191–198. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ferrari G, Pintucci G, Seghezzi G, Hyman
K, Galloway AC and Mignatti P: VEGF, a prosurvival factor, acts in
concert with TGF-beta1 to induce endothelial cell apoptosis. Proc
Natl Acad Sci USA. 103:17260–17265. 2006; View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Terme M, Pernot S, Marcheteau E, Sandoval
F, Benhamouda N, Colussi O, Dubreuil O, Carpentier AF, Tartour E
and Taieb J: VEGFA-VEGFR pathway blockade inhibits tumor-induced
regulatory T-cell proliferation in colorectal cancer. Cancer Res.
73:539–549. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hamzah J, Jugold M, Kiessling F, Rigby P,
Manzur M, Marti HH, Rabie T, Kaden S, Gröne HJ, Hämmerling GJ, et
al: Vascular normalization in Rgs5-deficient tumours promotes
immune destruction. Nature. 453:410–414. 2008. View Article : Google Scholar : PubMed/NCBI
|
